{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T16:50:56Z","timestamp":1779123056011,"version":"3.51.4"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Erik, Karin and G\u00f6sta Selander Foundation"},{"DOI":"10.13039\/501100001862","name":"the Swedish Research council","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001862","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100012538","name":"Swedish Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012538","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004063","name":"Knut and Alice Wallenberg Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Radiumhemmet Cancerf\u00f6reningen"},{"name":"Berth von Kantzows foundation and Ollie & Elof Ericssons foundation"},{"DOI":"10.13039\/100012538","name":"the Swedish Cancer foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012538","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Karolinska Institutet Ming Wai Lau Centre for Reparative Medicine Seed Grant"},{"name":"the County Councils of Stockholm"},{"name":"the County Councils of Uppsala"},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML), characterized by a fusion between the\n                      <jats:italic>PML<\/jats:italic>\n                      and\n                      <jats:italic>RARA<\/jats:italic>\n                      genes and by a block in the myeloid maturation at the promyelocytic stage.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study investigates the epigenetic landscape of APL by integrating ChIP-seq data on eight histone modifications and RNA-seq in APL as well as non-APL AML. APL showed a distinct chromatin profile that differed from non-APL AML.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We describe APL-specific changes in H3K27ac, H3K9me3, and H3K27me3 with impact on enhancer activity, repression of transposable elements, and Polycomb regulated gene repression. The APL-specific H3K27ac pattern identifies APL-specific enhancer and super-enhancer regions, including a subset of enhancers that are bound by the PML-RARA fusion protein. While chromatin bound specifically by PML-RARA were dominantly active, APL was also characterized by gain of APL-specific heterochromatin states with significant gains of H3K9me3 enriched lamina-associated domains and the transposable elements LINE, LTR, and SINE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings suggest a unique enhancer and heterochromatin profile in APL, with implications for transcription regulation and treatment response. These findings offer novel insights into the pathogenesis of APL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13073-025-01565-y","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:54:40Z","timestamp":1761825280000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Disease-specific epigenetic deregulation of enhancers, transposons, and polycomb targets in acute promyelocytic leukemia"],"prefix":"10.1186","volume":"17","author":[{"given":"Xiangfu","family":"Zhong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Cordeddu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelica","family":"Gamboa-Cedeno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Bengtz\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl","family":"Ekwall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Lennartsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00f6ren","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"1565_CR1","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","volume":"133","author":"MA Sanz","year":"2019","unstructured":"Sanz MA, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019;133:1630\u201343.","journal-title":"Blood"},{"key":"1565_CR2","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1038\/leu.2017.71","volume":"31","author":"S Lehmann","year":"2017","unstructured":"Lehmann S, et al. Early death rates remain high in high-risk APL: update from the Swedish Acute Leukemia Registry 1997\u20132013. Leukemia. 2017;31:1457\u20139.","journal-title":"Leukemia"},{"key":"1565_CR3","doi-asserted-by":"crossref","unstructured":"Voso MT, et al. Acute promyelocytic leukemia: Long-term outcomes from the HARMONY project. Blood. 2024;145(2):234\u201343.","DOI":"10.1182\/blood.2024026186"},{"key":"1565_CR4","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/35901","volume":"391","author":"F Grignani","year":"1998","unstructured":"Grignani F, et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature. 1998;391:815\u20138.","journal-title":"Nature"},{"key":"1565_CR5","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/ng0298-126","volume":"18","author":"LZ He","year":"1998","unstructured":"He LZ, et al. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet. 1998;18:126\u201335.","journal-title":"Nat Genet"},{"key":"1565_CR6","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S1097-2765(00)80322-6","volume":"5","author":"RJ Lin","year":"2000","unstructured":"Lin RJ, Evans RM. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol Cell. 2000;5:821\u201330.","journal-title":"Mol Cell"},{"key":"1565_CR7","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/35895","volume":"391","author":"RJ Lin","year":"1998","unstructured":"Lin RJ, et al. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature. 1998;391:811\u20134.","journal-title":"Nature"},{"key":"1565_CR8","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1182\/blood.2020005698","volume":"137","author":"Y Tan","year":"2021","unstructured":"Tan Y, et al. A PML\/RAR\u03b1 direct target atlas redefines transcriptional deregulation in acute promyelocytic leukemia. Blood. 2021;137:1503\u201316.","journal-title":"Blood"},{"key":"1565_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36262-0","volume":"14","author":"W Villiers","year":"2023","unstructured":"Villiers W, et al. Multi-omics and machine learning reveal context-specific gene regulatory activities of PML::RARA in acute promyelocytic leukemia. Nat Commun. 2023;14:724.","journal-title":"Nat Commun"},{"key":"1565_CR10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1385\/SCR:1:3:197","volume":"1","author":"S Sell","year":"2005","unstructured":"Sell S. Leukemia: stem cells, maturation arrest, and differentiation therapy. Stem Cell Rev. 2005;1:197\u2013205.","journal-title":"Stem Cell Rev"},{"key":"1565_CR11","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.ccr.2013.11.003","volume":"24","author":"B Chapuy","year":"2013","unstructured":"Chapuy B, et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell. 2013;24:777\u201390.","journal-title":"Cancer Cell"},{"key":"1565_CR12","doi-asserted-by":"publisher","first-page":"21931","DOI":"10.1073\/pnas.1016071107","volume":"107","author":"MP Creyghton","year":"2010","unstructured":"Creyghton MP, et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc Natl Acad Sci U S A. 2010;107:21931\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1565_CR13","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41587-020-0439-x","volume":"38","author":"PA Ewels","year":"2020","unstructured":"Ewels PA, et al. The nf-core framework for community-curated bioinformatics pipelines. Nat Biotechnol. 2020;38:276\u20138.","journal-title":"Nat Biotechnol"},{"key":"1565_CR14","doi-asserted-by":"publisher","first-page":"W160","DOI":"10.1093\/nar\/gkw257","volume":"44","author":"F Ram\u00edrez","year":"2016","unstructured":"Ram\u00edrez F, et al. deepTools2: a next generation web server for deep-sequencing data analysis. Nucleic Acids Res. 2016;44:W160\u20135.","journal-title":"Nucleic Acids Res"},{"key":"1565_CR15","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1038\/nprot.2012.101","volume":"7","author":"J Feng","year":"2012","unstructured":"Feng J, Liu T, Qin B, Zhang Y, Liu XS. Identifying ChIP-seq enrichment using MACS. Nat Protoc. 2012;7:1728\u201340.","journal-title":"Nat Protoc"},{"key":"1565_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2008-9-9-r137","volume":"9","author":"Y Zhang","year":"2008","unstructured":"Zhang Y, et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 2008;9:R137.","journal-title":"Genome Biol"},{"key":"1565_CR17","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nature10730","volume":"481","author":"CS Ross-Innes","year":"2012","unstructured":"Ross-Innes CS, et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature. 2012;481:389\u201393.","journal-title":"Nature"},{"key":"1565_CR18","unstructured":"Stark R, Brown G. DiffBind : differential binding analysis of ChIP-Seq peak data. 2013.\u00a0http:\/\/bioconductor.statistik.tu-dortmund.de\/packages\/2.13\/bioc\/vignettes\/DiffBind\/inst\/doc\/DiffBind.pdf."},{"key":"1565_CR19","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nbt.1754","volume":"29","author":"JT Robinson","year":"2011","unstructured":"Robinson JT, et al. Integrative genomics viewer. Nat Biotechnol. 2011;29:24\u20136.","journal-title":"Nat Biotechnol"},{"key":"1565_CR20","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/bib\/bbs017","volume":"14","author":"H Thorvaldsd\u00f3ttir","year":"2013","unstructured":"Thorvaldsd\u00f3ttir H, Robinson JT, Mesirov JP. Integrative genomics viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform. 2013;14:178\u201392.","journal-title":"Brief Bioinform"},{"key":"1565_CR21","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1158\/0008-5472.CAN-17-0337","volume":"77","author":"JT Robinson","year":"2017","unstructured":"Robinson JT, Thorvaldsd\u00f3ttir H, Wenger AM, Zehir A, Mesirov JP. Variant review with the integrative genomics viewer. Cancer Res. 2017;77:e31\u20134.","journal-title":"Cancer Res"},{"key":"1565_CR22","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nmeth.1906","volume":"9","author":"J Ernst","year":"2012","unstructured":"Ernst J, Kellis M. Chromhmm: automating chromatin-state discovery and characterization. Nat Methods. 2012;9:215\u20136.","journal-title":"Nat Methods"},{"key":"1565_CR23","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.cell.2013.03.035","volume":"153","author":"WA Whyte","year":"2013","unstructured":"Whyte WA, et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell. 2013;153:307\u201319.","journal-title":"Cell"},{"key":"1565_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-11-165","volume":"11","author":"RC McLeay","year":"2010","unstructured":"McLeay RC, Bailey TL. Motif enrichment analysis: a unified framework and an evaluation on ChIP data. BMC Bioinformatics. 2010;11:165.","journal-title":"BMC Bioinformatics"},{"key":"1565_CR25","doi-asserted-by":"crossref","unstructured":"Wang P, et al. Chromatin topology reorganization and transcription repression by PML-RAR\u03b1 in acute promyeloid leukemia. Genome Biol. 2020;21:110.","DOI":"10.1186\/s13059-020-02030-2"},{"key":"1565_CR26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.cels.2016.07.002","volume":"3","author":"NC Durand","year":"2016","unstructured":"Durand NC, et al. Juicer provides a one-click system for analyzing loop-resolution Hi-C experiments. Cell Syst. 2016;3:95\u20138.","journal-title":"Cell Syst"},{"key":"1565_CR27","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1038\/leu.2017.48","volume":"31","author":"M Wang","year":"2017","unstructured":"Wang M, et al. Validation of risk stratification models in acute myeloid leukemia using sequencing-based molecular profiling. Leukemia. 2017;31:2029\u201336.","journal-title":"Leukemia"},{"key":"1565_CR28","unstructured":"Andrews S, et al. FastQC: a quality control tool for high throughput sequence data. [Preprint]. 2010."},{"key":"1565_CR29","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1093\/bioinformatics\/btw354","volume":"32","author":"P Ewels","year":"2016","unstructured":"Ewels P, Magnusson M, Lundin S, K\u00e4ller M. MultiQC: summarize analysis results for multiple tools and samples in a single report. Bioinformatics. 2016;32:3047\u20138.","journal-title":"Bioinformatics"},{"key":"1565_CR30","unstructured":"Krueger F. Trim Galore!: A wrapper around Cutadapt and FastQC to consistently apply adapter and quality trimming to FastQ files, with extra functionality for RRBS data. Babraham Institute. 2015."},{"key":"1565_CR31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, et al. Star: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15\u201321.","journal-title":"Bioinformatics"},{"key":"1565_CR32","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao Y, Smyth GK, Shi W. Featurecounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30:923\u201330.","journal-title":"Bioinformatics"},{"key":"1565_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"1565_CR34","doi-asserted-by":"publisher","first-page":"4878","DOI":"10.1182\/blood-2011-10-383083","volume":"119","author":"RI Koleva","year":"2012","unstructured":"Koleva RI, et al. C\/EBP\u03b1 and DEK coordinately regulate myeloid differentiation. Blood. 2012;119:4878\u201388.","journal-title":"Blood"},{"key":"1565_CR35","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1038\/ng.430","volume":"41","author":"E Papaemmanuil","year":"2009","unstructured":"Papaemmanuil E, et al. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat Genet. 2009;41:1006\u201310.","journal-title":"Nat Genet"},{"key":"1565_CR36","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1084\/jem.20071875","volume":"205","author":"K Petropoulos","year":"2008","unstructured":"Petropoulos K, et al. A novel role for Lef-1, a central transcription mediator of Wnt signaling, in leukemogenesis. J Exp Med. 2008;205:515\u201322.","journal-title":"J Exp Med"},{"key":"1565_CR37","doi-asserted-by":"publisher","first-page":"11148","DOI":"10.1074\/jbc.M116.717801","volume":"291","author":"S Yu","year":"2016","unstructured":"Yu S, et al. Hematopoietic and leukemic stem cells have distinct dependence on Tcf1 and Lef1 transcription factors. J Biol Chem. 2016;291:11148\u201360.","journal-title":"J Biol Chem"},{"key":"1565_CR38","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1182\/blood-2012-02-411827","volume":"120","author":"KH Metzeler","year":"2012","unstructured":"Metzeler KH, et al. High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia. Blood. 2012;120:2118\u201326.","journal-title":"Blood"},{"key":"1565_CR39","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.cell.2007.01.003","volume":"128","author":"Z Tothova","year":"2007","unstructured":"Tothova Z, et al. Foxos are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell. 2007;128:325\u201339.","journal-title":"Cell"},{"key":"1565_CR40","doi-asserted-by":"publisher","first-page":"5512","DOI":"10.1182\/bloodadvances.2020001826","volume":"4","author":"V Govindarajah","year":"2020","unstructured":"Govindarajah V, et al. Foxo activity adaptation safeguards the hematopoietic stem cell compartment in hyperglycemia. Blood Adv. 2020;4:5512\u201326.","journal-title":"Blood Adv"},{"key":"1565_CR41","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.exphem.2012.11.008","volume":"41","author":"A Joshi","year":"2013","unstructured":"Joshi A, Hannah R, Diamanti E, G\u00f6ttgens B. Gene set control analysis predicts hematopoietic control mechanisms from genome-wide transcription factor binding data. Exp Hematol. 2013;41:354-66.e14.","journal-title":"Exp Hematol"},{"key":"1565_CR42","doi-asserted-by":"crossref","unstructured":"Bozhilov YK, Hsu I, Brown EJ, Wilkinson AC. In vitro human haematopoietic stem cell expansion and differentiation. Cells. 2023;12(6):896.","DOI":"10.3390\/cells12060896"},{"key":"1565_CR43","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/MOH.0000000000000441","volume":"25","author":"V Menon","year":"2018","unstructured":"Menon V, Ghaffari S. Transcription factors FOXO in the regulation of homeostatic hematopoiesis. Curr Opin Hematol. 2018;25:290\u20138.","journal-title":"Curr Opin Hematol"},{"key":"1565_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00212-4","volume":"8","author":"A Schwarzer","year":"2017","unstructured":"Schwarzer A, et al. The non-coding RNA landscape of human hematopoiesis and leukemia. Nat Commun. 2017;8:218.","journal-title":"Nat Commun"},{"key":"1565_CR45","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.1365-2613.2012.00815.x","volume":"93","author":"X Qiu","year":"2012","unstructured":"Qiu X, et al. Oestrogen-deficiency inducing haematopoiesis dysfunction via reduction in haematopoietic stem cells and haematopoietic growth factors in rats. Int J Exp Pathol. 2012;93:179\u201387.","journal-title":"Int J Exp Pathol"},{"key":"1565_CR46","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1158\/1535-7163.MCT-17-0292","volume":"16","author":"S-G Rota","year":"2017","unstructured":"Rota S-G, et al. Estrogen receptor \u03b2 is a novel target in acute myeloid leukemia. Mol Cancer Ther. 2017;16:2618\u201326.","journal-title":"Mol Cancer Ther"},{"key":"1565_CR47","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/febs.17263","volume":"292","author":"J Zhu","year":"2025","unstructured":"Zhu J, et al. The AXL inhibitor bemcentinib overcomes microenvironment-mediated resistance to pioglitazone in acute myeloid leukemia. FEBS J. 2025;292:115\u201328.","journal-title":"FEBS J"},{"key":"1565_CR48","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.3324\/haematol.2016.163022","volume":"102","author":"G Daniele","year":"2017","unstructured":"Daniele G, et al. Epigenetically induced ectopic expression of UNCX impairs the proliferation and differentiation of myeloid cells. Haematologica. 2017;102:1204\u201314.","journal-title":"Haematologica"},{"key":"1565_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02033-8","volume":"23","author":"S Liu","year":"2024","unstructured":"Liu S, et al. Effects of super-enhancers in cancer metastasis: mechanisms and therapeutic targets. Mol Cancer. 2024;23:122.","journal-title":"Mol Cancer"},{"key":"1565_CR50","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/s12276-020-0428-7","volume":"52","author":"Q Jia","year":"2020","unstructured":"Jia Q, Chen S, Tan Y, Li Y, Tang F. Oncogenic super-enhancer formation in tumorigenesis and its molecular mechanisms. Exp Mol Med. 2020;52:713\u201323.","journal-title":"Exp Mol Med"},{"key":"1565_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04673-4","volume":"13","author":"Q Liu","year":"2022","unstructured":"Liu Q, Guo L, Lou Z, Xiang X, Shao J. Super-enhancers and novel therapeutic targets in colorectal cancer. Cell Death Dis. 2022;13:228.","journal-title":"Cell Death Dis"},{"key":"1565_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-020-0108-z","volume":"4","author":"F Tang","year":"2020","unstructured":"Tang F, Yang Z, Tan Y, Li Y. Super-enhancer function and its application in cancer targeted therapy. NPJ Precis Oncol. 2020;4:2.","journal-title":"NPJ Precis Oncol"},{"key":"1565_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03538-6","volume":"12","author":"S Cui","year":"2021","unstructured":"Cui S, et al. EphA2 super-enhancer promotes tumor progression by recruiting FOSL2 and TCF7L2 to activate the target gene EphA2. Cell Death Dis. 2021;12:264.","journal-title":"Cell Death Dis"},{"key":"1565_CR54","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.ccell.2018.10.008","volume":"34","author":"H Celik","year":"2018","unstructured":"Celik H, et al. JARID2 functions as a tumor suppressor in myeloid neoplasms by repressing self-renewal in hematopoietic progenitor cells. Cancer Cell. 2018;34:741-756.e8.","journal-title":"Cancer Cell"},{"key":"1565_CR55","doi-asserted-by":"publisher","first-page":"3840","DOI":"10.1091\/mbc.e09-02-0146","volume":"20","author":"A Aslam","year":"2009","unstructured":"Aslam A, Mittal S, Koch F, Andrau J-C, Winkler GS. The Ccr4\u2013not deadenylase subunits CNOT7 and CNOT8 have overlapping roles and modulate cell proliferation. Mol Biol Cell. 2009;20:3840\u201350.","journal-title":"Mol Biol Cell"},{"key":"1565_CR56","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1182\/blood-2024-204988","volume":"144","author":"EK Schweighart","year":"2024","unstructured":"Schweighart EK, et al. Characterizing the bone marrow stromal niche in pediatric acute myeloid leukemia. Blood. 2024;144:4062\u20134062.","journal-title":"Blood"},{"key":"1565_CR57","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/s43018-022-00394-x","volume":"3","author":"KH Lin","year":"2022","unstructured":"Lin KH, et al. P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia. Nat Cancer. 2022;3:837\u201351.","journal-title":"Nat Cancer"},{"key":"1565_CR58","doi-asserted-by":"publisher","first-page":"5160","DOI":"10.1038\/s41388-022-02505-5","volume":"41","author":"LM Lee","year":"2022","unstructured":"Lee LM, et al. A novel network pharmacology approach for leukaemia differentiation therapy using Mogrify\u00ae. Oncogene. 2022;41:5160\u201375.","journal-title":"Oncogene"},{"key":"1565_CR59","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/nm.2753","volume":"18","author":"H Peinado","year":"2012","unstructured":"Peinado H, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012;18:883\u201391.","journal-title":"Nat Med"},{"key":"1565_CR60","doi-asserted-by":"publisher","first-page":"4920","DOI":"10.1158\/0008-5472.CAN-12-0925","volume":"72","author":"A Bobrie","year":"2012","unstructured":"Bobrie A, et al. Rab27a supports exosome-dependent and -independent mechanisms that modify the tumor microenvironment and can promote tumor progression. Cancer Res. 2012;72:4920\u201330.","journal-title":"Cancer Res"},{"key":"1565_CR61","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41416-022-01833-3","volume":"127","author":"F Schmid","year":"2022","unstructured":"Schmid F, et al. Calcium-binding protein S100P is a new target gene of MACC1, drives colorectal cancer metastasis and serves as a prognostic biomarker. Br J Cancer. 2022;127:675\u201385.","journal-title":"Br J Cancer"},{"key":"1565_CR62","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1158\/0008-5472.CAN-05-2605","volume":"66","author":"G Wang","year":"2006","unstructured":"Wang G, et al. Induction of metastasis by S100P in a rat mammary model and its association with poor survival of breast cancer patients. Cancer Res. 2006;66:1199\u2013207.","journal-title":"Cancer Res"},{"key":"1565_CR63","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2024.2400620","volume":"29","author":"G Zhu","year":"2024","unstructured":"Zhu G, et al. Elucidating the immune landscape and potential prognostic model in acute myeloid leukemia with TP53 mutation. Hematology. 2024;29:2400620.","journal-title":"Hematology"},{"key":"1565_CR64","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ydbio.2015.01.011","volume":"400","author":"T Hochgreb-H\u00e4gele","year":"2015","unstructured":"Hochgreb-H\u00e4gele T, Koo DES, Bronner ME. Znf385C mediates a novel p53-dependent transcriptional switch to control timing of facial bone formation. Dev Biol. 2015;400:23\u201332.","journal-title":"Dev Biol"},{"key":"1565_CR65","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.cell.2017.04.022","volume":"169","author":"B van Steensel","year":"2017","unstructured":"van Steensel B, Belmont AS. Lamina-associated domains: links with chromosome architecture, heterochromatin, and gene repression. Cell. 2017;169:780\u201391.","journal-title":"Cell"},{"key":"1565_CR66","doi-asserted-by":"publisher","unstructured":"Manzo SG. et al. Chromatin protein complexes involved in gene repression in lamina-associated domains. bioRxiv.\u00a02024. https:\/\/doi.org\/10.1101\/2024.05.05.592629.","DOI":"10.1101\/2024.05.05.592629"},{"key":"1565_CR67","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1093\/bioinformatics\/btv422","volume":"31","author":"Y Jin","year":"2015","unstructured":"Jin Y, Tam OH, Paniagua E, Hammell M. TEtranscripts: a package for including transposable elements in differential expression analysis of RNA-seq datasets. Bioinformatics. 2015;31:3593\u20139.","journal-title":"Bioinformatics"},{"key":"1565_CR68","doi-asserted-by":"publisher","unstructured":"Gunsalus LM, Keiser MJ, Pollard KS. In silico discovery of repetitive elements as key sequence determinants of 3D genome folding. Cell Genom. 2023. https:\/\/doi.org\/10.1016\/j.xgen.2023.100410.","DOI":"10.1016\/j.xgen.2023.100410"},{"key":"1565_CR69","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1182\/blood-2004-07-2761","volume":"106","author":"JC Reed","year":"2005","unstructured":"Reed JC, Pellecchia M. Apoptosis-based therapies for hematologic malignancies. Blood. 2005;106:408\u201318.","journal-title":"Blood"},{"key":"1565_CR70","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/nrc2943","volume":"10","author":"H de Th\u00e9","year":"2010","unstructured":"de Th\u00e9 H, Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer. 2010;10:775\u201383.","journal-title":"Nat Rev Cancer"},{"key":"1565_CR71","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1084\/jem.20131121","volume":"210","author":"GA Dos Santos","year":"2013","unstructured":"Dos Santos GA, Kats L, Pandolfi PP. Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. J Exp Med. 2013;210:2793\u2013802.","journal-title":"J Exp Med"},{"key":"1565_CR72","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ccr.2009.12.045","volume":"17","author":"K Wang","year":"2010","unstructured":"Wang K, et al. PML\/RARalpha targets promoter regions containing PU.1 consensus and RARE half sites in acute promyelocytic leukemia. Cancer Cell. 2010;17:186\u201397.","journal-title":"Cancer Cell"},{"key":"1565_CR73","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ccr.2009.12.042","volume":"17","author":"JHA Martens","year":"2010","unstructured":"Martens JHA, et al. PML-RARalpha\/RXR alters the epigenetic landscape in acute promyelocytic leukemia. Cancer Cell. 2010;17:173\u201385.","journal-title":"Cancer Cell"},{"key":"1565_CR74","first-page":"2445","volume":"109","author":"W Xu","year":"2024","unstructured":"Xu W, et al. ETV6::ACSL6 translocation-driven super-enhancer activation leads to eosinophilia in acute lymphoblastic leukemia through IL-3 overexpression. Haematologica. 2024;109:2445\u201358.","journal-title":"Haematologica"},{"key":"1565_CR75","doi-asserted-by":"publisher","first-page":"5100","DOI":"10.1182\/bloodadvances.2023012161","volume":"8","author":"D Weichenhan","year":"2024","unstructured":"Weichenhan D, et al. Altered enhancer-promoter interaction leads to MNX1 expression in pediatric acute myeloid leukemia with t(7;12)(q36;p13). Blood Adv. 2024;8:5100\u201311.","journal-title":"Blood Adv"},{"key":"1565_CR76","doi-asserted-by":"crossref","unstructured":"Tontonoz P, Nagy L, Alvarez JGA, Thomazy VA, Evans RM. PPAR\u03b3 promotes monocyte\/macrophage differentiation and uptake of oxidized LDL. Cell. 1998;93:241\u201352.","DOI":"10.1016\/S0092-8674(00)81575-5"},{"key":"1565_CR77","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1124\/mol.104.006445","volume":"67","author":"A Szanto","year":"2005","unstructured":"Szanto A, Nagy L. Retinoids potentiate peroxisome proliferator-activated receptor gamma action in differentiation, gene expression, and lipid metabolic processes in developing myeloid cells. Mol Pharmacol. 2005;67:1935\u201343.","journal-title":"Mol Pharmacol"},{"key":"1565_CR78","doi-asserted-by":"publisher","first-page":"6078","DOI":"10.1182\/blood-2011-07-365080","volume":"118","author":"S Avagyan","year":"2011","unstructured":"Avagyan S, Aguilo F, Kamezaki K, Snoeck H-W. Quantitative trait mapping reveals a regulatory axis involving peroxisome proliferator-activated receptors, PRDM16, transforming growth factor-\u03b22 and FLT3 in hematopoiesis. Blood. 2011;118:6078\u201386.","journal-title":"Blood"},{"key":"1565_CR79","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41417-024-00729-z","volume":"31","author":"JB Park","year":"2024","unstructured":"Park JB, et al. Neddylation of insulin receptor substrate acts as a bona fide regulator of insulin signaling and its implications for cancer cell migration. Cancer Gene Ther. 2024;31:599\u2013611.","journal-title":"Cancer Gene Ther"},{"key":"1565_CR80","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/789174","volume":"2012","author":"B Arcidiacono","year":"2012","unstructured":"Arcidiacono B, et al. Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. Exp Diabetes Res. 2012;2012:789174.","journal-title":"Exp Diabetes Res"},{"key":"1565_CR81","doi-asserted-by":"publisher","DOI":"10.1155\/2009\/571365","volume":"2009","author":"DP Foti","year":"2009","unstructured":"Foti DP, Paonessa F, Chiefari E, Brunetti A. New target genes for the peroxisome proliferator-activated receptor-\u03b3 (PPAR\u03b3) antitumour activity: perspectives from the insulin receptor. PPAR Res. 2009;2009:571365.","journal-title":"PPAR Res"},{"key":"1565_CR82","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S1097-2765(00)80047-7","volume":"1","author":"E Mueller","year":"1998","unstructured":"Mueller E, et al. Terminal differentiation of human breast cancer through PPAR\u03b3. Mol Cell. 1998;1:465\u201370.","journal-title":"Mol Cell"},{"key":"1565_CR83","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1677\/ERC-07-0226","volume":"15","author":"V Costa","year":"2008","unstructured":"Costa V, et al. The insulin receptor: a new anticancer target for peroxisome proliferator-activated receptor-gamma (PPARgamma) and thiazolidinedione-PPARgamma agonists. Endocr Relat Cancer. 2008;15:325\u201335.","journal-title":"Endocr Relat Cancer"},{"key":"1565_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33147-6","volume":"13","author":"S Tessier","year":"2022","unstructured":"Tessier S, et al. Exploration of nuclear body-enhanced sumoylation reveals that PML represses 2-cell features of embryonic stem cells. Nat Commun. 2022;13:5726.","journal-title":"Nat Commun"},{"key":"1565_CR85","doi-asserted-by":"publisher","first-page":"4102","DOI":"10.1038\/sj.emboj.7601839","volume":"26","author":"H Sun","year":"2007","unstructured":"Sun H, Leverson JD, Hunter T. Conserved function of RNF4 family proteins in eukaryotes: targeting a ubiquitin ligase to SUMOylated proteins. EMBO J. 2007;26:4102\u201312.","journal-title":"EMBO J"},{"key":"1565_CR86","doi-asserted-by":"publisher","first-page":"10190","DOI":"10.1074\/jbc.M611429200","volume":"282","author":"XH Mascle","year":"2007","unstructured":"Mascle XH, Germain-Desprez D, Huynh P, Estephan P, Aubry M. Sumoylation of the transcriptional intermediary factor 1beta (TIF1beta), the co-repressor of the KRAB multifinger proteins, is required for its transcriptional activity and is modulated by the KRAB domain. J Biol Chem. 2007;282:10190\u2013202.","journal-title":"J Biol Chem"},{"key":"1565_CR87","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-017-0374-4","volume":"24","author":"P Czerwi\u0144ska","year":"2017","unstructured":"Czerwi\u0144ska P, Mazurek S, Wiznerowicz M. The complexity of TRIM28 contribution to cancer. J Biomed Sci. 2017;24:63.","journal-title":"J Biomed Sci"},{"key":"1565_CR88","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.cell.2015.08.037","volume":"163","author":"BX Yang","year":"2015","unstructured":"Yang BX, et al. Systematic identification of factors for provirus silencing in embryonic stem cells. Cell. 2015;163:230\u201345.","journal-title":"Cell"},{"key":"1565_CR89","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1158\/2159-8290.CD-23-0453","volume":"13","author":"P Bercier","year":"2023","unstructured":"Bercier P, et al. Structural basis of PML-RARA oncoprotein targeting by arsenic unravels a cysteine rheostat controlling PML body assembly and function. Cancer Discov. 2023;13:2548\u201365.","journal-title":"Cancer Discov"},{"key":"1565_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01004-y","volume":"14","author":"I Khan","year":"2024","unstructured":"Khan I, Amin MA, Eklund EA, Gartel AL. Regulation of HOX gene expression in AML. Blood Cancer J. 2024;14:42.","journal-title":"Blood Cancer J"},{"key":"1565_CR91","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1182\/blood.V101.4.1558","volume":"101","author":"A Thompson","year":"2003","unstructured":"Thompson A, et al. Global down-regulation of HOX gene expression in PML-RARalpha + acute promyelocytic leukemia identified by small-array real-time PCR. Blood. 2003;101:1558\u201365.","journal-title":"Blood"},{"key":"1565_CR92","doi-asserted-by":"publisher","unstructured":"Zhong X, Lehmann S. Disease specific epigenetic deregulation of enhancers, transposons and polycomb in acute promyelocytic leukemia. 2025. Datasets, Zenodo. https:\/\/doi.org\/10.5281\/zenodo.17296520.","DOI":"10.5281\/zenodo.17296520"},{"key":"1565_CR93","unstructured":"Gamboa-Cedeno A, Zhong X, Lennartsson A, Lehmann S. Disease specific epigenetic deregulation of enhancers, transposons and polycomb targets in acute promyelocytic leukemia. Datasets. Gene Expression Omnibus (GEO). 2025.\u00a0https:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=gse305480."},{"key":"1565_CR94","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1182\/blood-2013-02-485771","volume":"123","author":"N Rapin","year":"2014","unstructured":"Rapin N, et al. Comparing cancer vs normal gene expression profiles identifies new disease entities and common transcriptional programs in AML patients. Blood. 2014;123:894\u2013904.","journal-title":"Blood"},{"key":"1565_CR95","doi-asserted-by":"crossref","unstructured":"Zhong X. Disease specific epigenetic deregulation of enhancers, transposons and polycomb targets in acute promyelocytic leukemia. 2025. Github https:\/\/github.com\/joey0214\/zhong_etal_apl_epigenetic_2025.","DOI":"10.1186\/s13073-025-01565-y"}],"container-title":["Genome Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-025-01565-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13073-025-01565-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-025-01565-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:05:54Z","timestamp":1761829554000},"score":1,"resource":{"primary":{"URL":"https:\/\/genomemedicine.biomedcentral.com\/articles\/10.1186\/s13073-025-01565-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":95,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1565"],"URL":"https:\/\/doi.org\/10.1186\/s13073-025-01565-y","relation":{},"ISSN":["1756-994X"],"issn-type":[{"value":"1756-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Bone marrow samples for the study were aspirated after written and oral informed consent during the routine diagnostic bone marrow examination at diagnosis of AML and APL as well as during bone marrow aspiration in healthy volunteers. The study was approved by the regional ethical review board in Stockholm, Sweden, following the Declaration of Helsinki, with reference number 2014\/1228\u201331\/4.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"135"}}